CureVac (CVAC) said Monday the US Food and Drug Administration has cleared the company to initiate a phase 1 study of its experimental mRNA-based therapy, CVHNLC, in patients with squamous non-small cell lung cancer.
The company said the open-label, dose-finding study will evaluate the safety and tolerability of CVHNLC in combination with pembrolizumab in patients.
The study will include a dose-escalation phase for first-line maintenance treatment following chemotherapy and pembrolizumab or pembrolizumab monotherapy, followed by an optional dose expansion phase combining CVHNLC with first-line chemotherapy and pembrolizumab, the drug developer said.
Shares of the company rose more than 1% in recent premarket activity.
Price: 2.62, Change: +0.03, Percent Change: +1.16
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.